Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncologists Embrace Part B Demo, Amgen Says; Big Test In Two Months

Executive Summary

The Medicare Part B market is holding up well in the early weeks of 2005 thanks to a $300 mil. demonstration project unveiled in November, Amgen told analysts Jan. 27 in New York

You may also be interested in...



Amgen Vectibix Assistance Program May Balance Part B Pricing Pressures

Amgen's pricing strategy for its colorectal cancer therapy Vectibix appears to balance the competing pricing pressures created by Medicare Part B's average sales price-based reimbursement methodology

Amgen Vectibix Assistance Program May Balance Part B Pricing Pressures

Amgen's pricing strategy for its colorectal cancer therapy Vectibix appears to balance the competing pricing pressures created by Medicare Part B's average sales price-based reimbursement methodology

CMS Extends Oncology Demo, Shifts Focus To Clinical Guideline Adherence

The Centers for Medicare & Medicaid Services is revising its cancer "quality of care" demonstration project to evaluate oncologists' adherence to evidence-based practice guidelines

Related Content

Topics

UsernamePublicRestriction

Register

PS045346

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel